A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus

Vaccine

Volumn 29, Issue 23, 2011, Pages 3951-3961

  Eliasson, Dubravka Grdic ^a   Helgeby, Anja ^a   Schön, Karin ^a   Nygren, Caroline ^a   El Bakkouri, Karim ^b,c   Fiers, Walter ^b,c   Saelens, Xavier ^b,c   Lövgren, Karin Bengtsson ^d   Nyström, Ida ^d   Lycke, Nils Y ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

^d ISCONOVA AB   (Sweden)

Author keywords

Adjuvant; Cholera toxin; CTA1 DD; Influenza A virus; M2e; Mucosal IgA; Vaccine vector

Indexed keywords

CTA1 DD; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA VACCINE; ISCOM; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; INFLUENZA A; INFLUENZA VACCINATION; INFLUENZA VIRUS A; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CHOLERA TOXIN; GENETIC VECTORS; HUMANS; IMMUNITY, MUCOSAL; IMMUNIZATION; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; ISCOMS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; MUCOUS MEMBRANE; ORTHOMYXOVIRIDAE INFECTIONS; REASSORTANT VIRUSES; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; VIRAL MATRIX PROTEINS;

EID: 79955643457     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.03.090     Document Type: Article

References (60)

1. Abramowicz M. FluMist: an intranasal live influenza vaccine. Med Lett Drugs Ther 2003, 45(August (1163)):65-66.
2. Levine M.M., Sztein M.B. Vaccine development strategies for improving immunization: the role of modern immunology. Nat Immunol 2004, 5(May (5)):460-464.
3. Nichol K.L., Treanor J.J. Vaccines for seasonal and pandemic influenza. J Infect Dis 2006, 194(November (Suppl. 2)):S111-S118.
4. Vajdy M. Immunity against mucosal pathogens 2008, Springer, Davis, CA.
5. Lambrecht B.N., Kool M., Willart M.A., Hammad H. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 2009, 21(February (1)):23-29.
6. Tagliabue A., Rappuoli R. Vaccine adjuvants: the dream becomes real. Hum Vaccin 2008, 4(September-October (5)):347-349.
7. Lycke N. Mechanisms of adjuvant action. Vaccine adjuvants and delivery systems 2007, 53-79. John Wiley & Sons, Hoboken, NJ. M. Singh (Ed.).
8. O'Neal C.J., Amaya E.I., Jobling M.G., Holmes R.K., Hol W.G. Crystal structures of an intrinsically active cholera toxin mutant yield insight into the toxin activation mechanism. Biochemistry 2004, 43(April (13)):3772-3782.
9. Lewis D.J., Huo Z., Barnett S., Kromann I., Giemza R., Galiza E., et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 2009, 4(9):e6999.
10. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004, 350(Febuary (9)):896-903.
11. Freytag L.C., Clements J.D., Grdic Eliasson D., Lycke N. Use of genetically or chemically detoxified mutants of Cholera and Escherichia coli heat-labile enterotoxins as mucosal adjuvants. New generation vaccines 2010, 273-283. Informa. 4th ed. M.M. Levine (Ed.).
12. Agren L.C., Ekman L., Lowenadler B., Lycke N.Y. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J Immunol 1997, 158(April (8)):3936-3946.
13. Cunningham K.A., Carey A.J., Lycke N., Timms P., Beagley K.W. CTA1-DD is an effective adjuvant for targeting anti-chlamydial immunity to the murine genital mucosa. J Reprod Immunol 2009, 81(July (1)):34-38.
14. Eliasson D.G., Bakkouri K.E., Schon K., Ramne A., Festjens E., Lowenadler B., et al. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine 2008, 26(February (9)):1243-1252.
15. Sundling C., Schon K., Morner A., Forsell M.N., Wyatt R.T., Thorstensson R., et al. CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization. J Gen Virol 2008, 89(Pt 12)(December):2954-2964.
16. Eriksson A.M., Schon K.M., Lycke N.Y. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues. J Immunol 2004, 173(September (5)):3310-3319.
17. Mowat A.M., Donachie A.M., Jagewall S., Schon K., Lowenadler B., Dalsgaard K., et al. CTA1-DD-immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen. J Immunol 2001, 167(September (6)):3398-3405.
18. Morein B., Sundquist B., Hoglund S., Dalsgaard K., Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 1984, 308(March-April (5958)):457-460.
19. Lovgren K., Morein B. The requirement of lipids for the formation of immunostimulating complexes (iscoms). Biotechnol Appl Biochem 1988, 10(April (2)):161-172.
20. Chen Q., Jackson H., Parente P., Luke T., Rizkalla M., Tai T.Y., et al. Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc Natl Acad Sci USA 2004, 101(June (25)):9363-9368.
21. Coulter A., Harris R., Davis R., Drane D., Cox J., Ryan D., et al. Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine. Vaccine 2003, 21(February (9-10)):946-949.
22. Heldens J.G., Pouwels H.G., Derks C.G., Van de Zande S.M., Hoeijmakers M.J. The first safe inactivated equine influenza vaccine formulation adjuvanted with ISCOM-Matrix that closes the immunity gap. Vaccine 2009, 27(September (40)):5530-5537.
23. Hu K.F., Lovgren-Bengtsson K., Morein B. Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv Drug Deliv Rev 2001, 51(September (1-3)):149-159.
24. Mumford J.A., Jessett D., Dunleavy U., Wood J., Hannant D., Sundquist B., et al. Antigenicity and immunogenicity of experimental equine influenza ISCOM vaccines. Vaccine 1994, 12(July (9)):857-863.
25. Rimmelzwaan G.F., Baars M., van Amerongen G., van Beek R., Osterhaus A.D. A single dose of an ISCOM influenza vaccine induces long-lasting protective immunity against homologous challenge infection but fails to protect Cynomolgus macaques against distant drift variants of influenza A (H3N2) viruses. Vaccine 2001, 20(October (1-2)):158-163.
26. Stewart T.J., Drane D., Malliaros J., Elmer H., Malcolm K.M., Cox J.C., et al. ISCOMATRIX adjuvant: an adjuvant suitable for use in anticancer vaccines. Vaccine 2004, 22(September (27-28)):3738-3743.
27. Sun H.X., Xie Y., Ye Y.P. ISCOMs and ISCOMATRIX. Vaccine 2009, 27(July (33)):4388-4401.
28. Dalsgaard K Saponin adjuvants. 3. Isolation of a substance from Quillaja saponaria Molina with adjuvant activity in food-and-mouth disease vaccines. Arch Gesamte Virusforsch 1974, 44(3):243-254.
29. Morein B., Hu K.F., Lövgren K., D'Hondt E. New ISCOMs meet unsettled vaccine demands. Vaccine adjuvants and delivery systems 2007, 191-222. Wiley & Sons, Inc., Emeryville, CA. M. Singh (Ed.).
30. Chwalek M., Lalun N., Bobichon H., Ple K., Voutquenne-Nazabadioko L. Structure-activity relationships of some hederagenin diglycosides: haemolysis, cytotoxicity and apoptosis induction. Biochim Biophys Acta 2006, 1760(September (9)):1418-1427.
31. Slovin S.F., Ragupathi G., Musselli C., Fernandez C., Diani M., Verbel D., et al. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer. Cancer Immunol Immunother 2005, 54(July (7)):694-702.
32. Helgeby A., Robson N.C., Donachie A.M., Beackock-Sharp H., Lovgren K., Schon K., et al. The combined CTA1-DD/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity to incorporated antigens by specific targeting of B cells. J Immunol 2006, 176(March (6)):3697-3706.
33. Kaiser J. A one-size-fits-all flu vaccine?. Science 2006, 312(April (5772)):380-382.
34. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999, 5(October (10)):1157-1163.
35. Slepushkin V.A., Katz J.M., Black R.A., Gamble W.C., Rota P.A., Cox N.J. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 1995, 13(15):1399-1402.
36. Tamura S., Miyata K., Matsuo K., Asanuma H., Takahashi H., Nakajima K., et al. Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. J Immunol 1996, 156(May (10)):3892-3900.
37. Tumpey T.M., Renshaw M., Clements J.D., Katz J.M. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol 2001, 75(June (11)):5141-5150.
38. Agren L., Norin M., Lycke N., Lowenadler B. Hydrophobicity engineering of cholera toxin A1 subunit in the strong adjuvant fusion protein CTA1-DD. Protein Eng 1999, 12(February (2)):173-178.
39. Spangler B.D. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol Rev 1992, 56(December (4)):622-647.
40. Tsuji T., Inoue T., Miyama A., Noda M. Glutamic acid-112 of the A subunit of heat-labile enterotoxin from enterotoxigenic Escherichia coli is important for ADP-ribosyltransferase activity. FEBS Lett 1991, 291(October (2)):319-321.
41. Lovgren K., Kaberg H., Morein B. An experimental influenza subunit vaccine (iscom): induction of protective immunity to challenge infection in mice after intranasal or subcutaneous administration. Clin Exp Immunol 1990, 82(December (3)):435-439.
42. Reed S.G., Bertholet S., Coler R.N., Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009, 30(January (1)):23-32.
43. Misplon J.A., Lo C.Y., Gabbard J.D., Tompkins S.M., Epstein S.L. Genetic control of immune responses to influenza A matrix 2 protein (M2). Vaccine 2010, 28(August (36)):5817-5827.
44. Gerhard W., Mozdzanowska K., Zharikova D. Prospects for universal influenza virus vaccine. Emerg Infect Dis 2006, 12(April (4)):569-574.
45. De Filette M., Min Jou W., Birkett A., Lyons K., Schultz B., Tonkyro A., et al. Universal influenza A vaccine: optimization of M2-based constructs. Virology 2005, 337(June (1)):149-161.
46. Fiers W., De Filette M., El Bakkouri K., Schepens B., Roose K., Schotsaert M., et al. M2e-based universal influenza A vaccine. Vaccine 2009, 27(October (45)):6280-6283.
47. Schotsaert M., De Filette M., Fiers W., Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 2009, 8(April (4)):499-508.
48. al-Mazrou A., Scheifele D.W., Soong T., Bjornson G. Comparison of adverse reactions to whole-virion and split-virion influenza vaccines in hospital personnel. CMAJ 1991, 145(August (3)):213-218.
49. De Filette M., Martens W., Roose K., Deroo T., Vervalle F., Bentahir M., et al. An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J Biol Chem 2008, 283(April (17)):11382-11387.
50. Mozdzanowska K., Furchner M., Zharikova D., Feng J., Gerhard W. Roles of CD4+ T-cell-independent and -dependent antibody responses in the control of influenza virus infection: evidence for noncognate CD4+ T-cell activities that enhance the therapeutic activity of antiviral antibodies. J Virol 2005, 79(May (10)):5943-5951.
51. Tompkins S.M., Zhao Z.S., Lo C.Y., Misplon J.A., Liu T., Ye Z., et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 2007, 13(March (3)):426-435.
52. Mozdzanowska K., Zharikova D., Cudic M., Otvos L., Gerhard W. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse. Virol J 2007, 4:118.
53. Mowat A.M., Donachie A.M., Reid G., Jarrett O. Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route. Immunology 1991, 72(March (3)):317-322.
54. Beacock-Sharp H., Donachie A.M., Robson N.C., Mowat A.M. A role for dendritic cells in the priming of antigen-specific CD4+ and CD8+ T lymphocytes by immune-stimulating complexes in vivo. Int Immunol 2003, 15(June (6)):711-720.
55. Robson N.C., Beacock-Sharp H., Donachie A.M., Mowat A.M. The role of antigen-presenting cells and interleukin-12 in the priming of antigen-specific CD4+ T cells by immune stimulating complexes. Immunology 2003, 110(September (1)):95-104.
56. Mahnke K., Guo M., Lee S., Sepulveda H., Swain S.L., Nussenzweig M., et al. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J Cell Biol 2000, 151(October (3)):673-684.
57. Marciani D.J., Press J.B., Reynolds R.C., Pathak A.K., Pathak V., Gundy L.E., et al. Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity. Vaccine 2000, 18(July (27)):3141-3151.
58. Robson N.C., Donachie A.M., Mowat A.M. Simultaneous presentation and cross-presentation of immune-stimulating complex-associated cognate antigen by antigen-specific B cells. Eur J Immunol 2008, 38(May (5)):1238-1246.
59. Heit A., Huster K.M., Schmitz F., Schiemann M., Busch D.H., Wagner H. CpG-DNA aided cross-priming by cross-presenting B cells. J Immunol 2004, 172(February (3)):1501-1507.
60. Macpherson A.J., Lamarre A., McCoy K., Harriman G.R., Odermatt B., Dougan G., et al. IgA production without mu or delta chain expression in developing B cells. Nat Immunol 2001, 2(July (7)):625-631.